Recurrence-free survival for low-risk endometrial cancer patients (grade 1 or 2 endometrioid histology, no lymphatic/vascular space invasion, less than 50% myometrial invasion) who did not receive any adjuvant therapy
| CTNNB1 mutation status | N | Events | Median recurrence-free survival, in years (CI) | P value |
| Wild-type | 91 | 19 | 11.3 (5.3 to NE) | |
| Mutant | 27 | 6 | 8.1 (2.8 to – NE) | |
| 0.65 |
NE, not evaluable.